SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 26.20 |
| Enterprise Value ($M) | -10.92 |
| Book Value ($M) | 35.31 |
| Book Value / Share | 0.97 |
| Price / Book | 0.74 |
| NCAV ($M) | 34.66 |
| NCAV / Share | 0.95 |
| Price / NCAV | 0.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.89 |
| Return on Assets (ROA) | -0.86 |
| Return on Equity (ROE) | -0.96 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.45 |
| Current Ratio | 10.45 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 38.33 |
| Assets | 38.98 |
| Liabilities | 3.67 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -32.49 |
| Net Income | -31.48 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -28.71 |
| Cash from Investing | 0.05 |
| Cash from Financing | 24.68 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Alger Associates Inc | 5.10 | 0.00 | |
| 13G | Tybourne Capital Management (hk) Ltd | 9.99 | ||
| 13G/A | Perceptive Advisors Llc | 9.90 | 0.16 | |
| 13G/A | Farallon Capital Partners, L.P. | 9.90 | 0.15 | |
| 13D/A | BML Investment Partners, L.P. | 4.80 | 1.53 | |
| 13D/A | Funicular Funds, LP | 5.59 | 0.00 | |
| 13D/A | Camac Fund, LP | 4.30 | 0.00 | |
| 13D/A | Wagner Paul A. | 5.21 | 48.64 | |
| 13D/A | ATG Fund II LLC | 4.00 | 0.00 | |
| 13G | Biotechnology Value Fund L P | 8.20 | ||
| 13G | JEC II Associates, LLC | 5.43 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| Powers of Attorney (contained in the signature page to this Annual Report on Form 10-K). | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,479 | 5,494 | 45.12 | |
| 508 | 9,223 | 5.51 | |
| 1,835 | 11,841 | 15.50 | |
| 1,198 | 803 | 149.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EVOK – Evoke Pharma, Inc. | EYEN – Eyenovia, Inc. |
| FBIO – Fortress Biotech, Inc. | FENC – Fennec Pharmaceuticals Inc. |
| FLGC – Flora Growth Corp. |
Financial data and stock pages provided by
Fintel.io